Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
Rev. Soc. Esp. Dolor ; 15(4): 219-227, mayo 2008. tab, graf
Article in Spanish | IBECS | ID: ibc-72937

ABSTRACT

Objetivos. Valorar la eficacia y seguridad de la analgesia postoperatoria con paracetamol intravenoso (P-iv). Pacientes y Métodos. Estudio prospectivo, multicéntrico observacional de pacientes sometidos a cirugía de dolor postoperatorio (DPO) leve y moderado que recibieron 4 dosis de P-iv 1 g /4-6h, solo o asociado con otros analgésicos. Se valoró el grado de dolor mediante la escala analógica visual, la afectación de la actividad, los efectos indeseables y la satisfacción del paciente. Periodo de estudio. 24 horas postoperatorias. Se aplicaron tests paramétricos o no paramétricos, o un modelo de regresión logística. Resultados. 725 pacientes evaluables, 56% con DPO previsiblemente leve y 43.3% DPO moderado. La EVA disminuyó significativamente en cada una de las valoraciones sucesivas (p<0,001), pero se mantuvo inferior a 30. El 46.3% de los pacientes recibieron P-iv como única analgesia. Metamizol fue el fármaco más frecuentemente asociado, seguido de opiáceos. Los niveles más altos de EVA se correlacionaron con la administración de analgésicos asociados, más interferencia con la actividad, más nauseas y vómitos y menor grado de satisfacción (p<0.05). El factor que se correlacionó con mayores valores de EVA fue el tipo de cirugía. No se observaron efectos indeseables relacionados con el P-iv. Conclusión. P-iv a dosis de 1 g/4-6 h es eficaz durante las primeras 24 horas del postoperatorio de cirugía que produce DPO leve a moderado, con pocos efectos indeseables. En la práctica anestésica se combina con frecuencia con otros analgésicos, siendo el más frecuente el metamizol seguido de opiáceos (AU)


Objective. Te evalúate the efficacy and safety of post-surgery analgesia with intravenous paracetamol (P-iv). Patient and Methods. Prospective, multicentre-observational study in patients who had surgery associated to mild or modérate postoperative pain (POP) that received 4 doses of P-iv 1 g /4-6h, alone or associated with other analgesics. The degree of pain by the visual analogue scale, effect on the activity, undesirable effects and patient satisfaction were recorded. Period of study: 24 hrs post-surgery. Statistics. Parametric or non-parametric, or a model of regression analysis. Results. 725 patient enrolled, 56% with mild POP and 43,3% modérate POP. EVA decreased significantly through the successive evaluations (p<0,001), but remained below 30. 46,3% received only P-iv as analgesic. Metamizol was the most frequently associated analgesic, followed by opiates. Higher levéis of EVA were correlated with: administration of associated analgesics, more interference with the activity, more nauseas and vomiting and smaller degree of satisfaction (p<0.05). The type of surgery was correlated with greater valúes of EVA. No undesirable effects caused by P-iv were observed. Conclusión. P-iv to 1 g/4-6 h is effective during the 24 first hours post-surgery that produces mild to modérate POP with few undesirable effects, and anaesthesia practice combines frequently P-iv with other analgesics, being the most frequent metamizol followed by opiates (AU)


Subject(s)
Humans , Male , Female , Pain, Postoperative/drug therapy , Acetaminophen/therapeutic use , /standards , Opioid Peptides/therapeutic use , Dipyrone/therapeutic use , Prospective Studies , Signs and Symptoms , Analgesia , Patient Satisfaction/statistics & numerical data , Patient Acceptance of Health Care/statistics & numerical data , Statistics, Nonparametric , Longitudinal Studies , Receptors, Opioid
2.
Vet Parasitol ; 90(3): 209-19, 2000 Jun 27.
Article in English | MEDLINE | ID: mdl-10842001

ABSTRACT

Vaccination of pigs of mixed genetic make-up, raised as rustically as done in rural Mexico, resulted in effective protection to experimental challenge against Taenia solium cysticercosis. Maximum protection was achieved if pigs were immunized at 70 days of age. There was large variation of viable parasite load within vaccinated pigs and controls, which is suggestive of significant genetic factors influencing susceptibility, besides immunization. Our results strengthen the advisability of pig vaccination for control of T. solium cysticercosis, since it lowers the number of viable cysticerci capable of transforming into tapeworms.


Subject(s)
Antibodies, Helminth/biosynthesis , Cysticercosis/veterinary , Swine Diseases/prevention & control , Taenia/immunology , Vaccination/veterinary , Age Factors , Animals , Cysticercosis/prevention & control , Genetic Predisposition to Disease , Mexico , Swine , Swine Diseases/genetics , Swine Diseases/immunology
3.
Phys Rev Lett ; 75(9): 1823-1826, 1995 Aug 28.
Article in English | MEDLINE | ID: mdl-10060400
4.
J Periodontol ; 62(7): 458-67, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1920013

ABSTRACT

Polypeptide growth factors are a class of potent natural biologic mediators which regulate many of the activities of wound healing including cell proliferation, migration, and metabolism. Platelet-derived growth factor (PDGF) and insulin-like growth factor-I (IGF-I) have been shown to regulate DNA and protein synthesis in bone cells in vitro and to interact synergistically to enhance soft tissue wound healing in vivo. We have hypothesized that the combination of PDGF and IGF-I may, therefore, enhance regeneration of both the soft and hard tissue components of the periodontium. To test this hypothesis we performed conventional periodontal surgery on all 4 quadrants of the mouth of 13 beagle dogs with naturally occurring periodontal disease. Following flap reflection, degranulation, and root planing, all premolar teeth in 2 quadrants of each dog received a combination of 3 micrograms of recombinant PDGF-B and IGF-I in a methylcellulose gel, while the premolar teeth in the contralateral quadrants received the gel alone. Teeth in 4 additional animals also received 125I-PDGF or 125I-IGF-I in the treated sites. The clearance rate of the 125I-labeled protein, changes in local bone metabolism, and amount of new bone and cementum with inserting collagen fibers were measured. The clearance studies revealed that the half-life of the factors at the site of application was 3.0 hours for IGF-I and to 4.2 hours for PDGF-B. Greater than 96% of the radio-labeled proteins was cleared by 96 hours and no radioactivity was detected 2 weeks after application. There was a significant (P less than 0.01) 2-fold increase in uptake of the bone-seeking radiopharmaceutical Technetium 99-MDP at 2 and 4 weeks in growth factor treated sites compared to controls, indicating that there was increased metabolic activity within the bone at these sites. Computer-aided histologic analyses of biopsies obtained at 2 and 5 weeks post-operatively revealed a significant (P less than 0.01), 5 to 10 fold increase in new bone and cementum in PDGF-B/IGF-I treated sites at both time points compared to controls receiving the placebo gel. The height and total area of new bone continued to increase from 2 to 5 weeks. The new bone underwent a normal maturation process as judged by histologic appearance. A physiologic periodontal ligament space was also formed between the new bone and new cementum. There was no increase in ankylosis in the treated sites.(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Insulin-Like Growth Factor I/therapeutic use , Periodontal Diseases/drug therapy , Platelet-Derived Growth Factor/therapeutic use , Alveolar Bone Loss/drug therapy , Alveolar Bone Loss/pathology , Alveolar Bone Loss/surgery , Alveolar Process/metabolism , Alveolar Process/pathology , Animals , Connective Tissue/pathology , Dogs , Drug Combinations , Female , Gingivitis/drug therapy , Gingivitis/pathology , Gingivitis/surgery , Insulin-Like Growth Factor I/administration & dosage , Insulin-Like Growth Factor I/pharmacokinetics , Iodine Radioisotopes , Metabolic Clearance Rate , Osteoblasts/pathology , Osteocytes/pathology , Periodontal Diseases/pathology , Periodontal Diseases/surgery , Periodontal Ligament/pathology , Platelet-Derived Growth Factor/administration & dosage , Platelet-Derived Growth Factor/pharmacokinetics , Recombinant Proteins , Regeneration/drug effects , Surgical Flaps , Technetium Tc 99m Medronate , Time Factors , Wound Healing/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...